Data updated: Mar 10, 2026
EXKIVITY
MOBOCERTINIB SUCCINATE
Approved 2021-09-15
1
Indication
--
Phase 3 Trials
1
Priority Reviews
4
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2021-09-15
- Routes
- ORAL
- Dosage Forms
- CAPSULE
EXKIVITY Approval History
Loading approval history...
What EXKIVITY Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EXKIVITY FDA Label Details
ProEXKIVITY Patents & Exclusivity
Latest Patent: May 2035
Exclusivity: Sep 2028
Patents (2 active)
US10227342
Expires May 13, 2035
US9796712
Expires May 13, 2035
Exclusivity
NCE
Until Sep 2026
ODE-374
Until Sep 2028
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.